Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: July 30, 2026
Reporting Period: Second Quarter ended June 30, 2026
This filing announces the financial results for the second quarter of 2026. The detailed results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the announcement of financial results but does not contain the specific numerical data within the body of this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to Exhibit 99.1 for this information.
Guidance, Outlook, and Risks
The text confirms the release of financial results but does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These details are located in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated July 30, 2026) for actual revenue, net income, and cash flow figures.
- Verify year-over-year and quarter-over-quarter growth rates in the attached press release.
- Check for any updated financial guidance or operational milestones mentioned in the full press release.
- Confirm the status of any clinical trials or regulatory approvals discussed in the full announcement.